GTHX — G1 Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $377.22m
- $360.81m
- $82.51m
- 51
- 10
- 94
- 50
Annual income statement for G1 Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 45.3 | 31.5 | 51.3 | 82.5 |
| Cost of Revenue | |||||
| Gross Profit | — | — | 29.5 | 47.6 | 75.3 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 129 | 142 | 174 | 187 | 122 |
| Operating Profit | -129 | -96.5 | -142 | -136 | -39.5 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -122 | -97.8 | -147 | -146 | -44.9 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -122 | -99.3 | -148 | -148 | -48 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -122 | -99.3 | -148 | -148 | -48 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -122 | -99.3 | -148 | -148 | -48 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -3.27 | -2.62 | -3.54 | -3.38 | -0.927 |